Investigating how RNA-binding affects treatment resistance in prostate cancer
Official title: RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance
Funded at Tulane University of Louisiana · NIH-11167304 · Data updated 2026-11-12
This study is looking at how a protein called the androgen receptor helps advanced prostate cancer resist treatments, with the goal of finding new ways to improve therapy and help patients live longer, healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $632,906 |
| NIH project number | 1R01CA301628-01 |
| Project ID | NIH-11167304 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced prostate cancer who have experienced disease progression despite current AR-targeting therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone AR-targeting therapies may not benefit from this research.
What this research studies
This research focuses on understanding how the androgen receptor (AR) contributes to resistance against therapies for advanced prostate cancer. It explores the mechanisms by which AR can reactivate cancer growth despite treatment with drugs like enzalutamide and abiraterone. By examining the RNA-binding capabilities of AR and its role in regulating splicing factors, the study aims to uncover new strategies to delay or prevent disease progression. Patients may benefit from insights that could lead to more effective treatments tailored to combat resistance.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve treatment outcomes for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results in understanding AR's role in cancer progression, suggesting that this approach could yield significant insights.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Dong, Yan — Tulane University of Louisiana
- Study coordinator: Dong, Yan
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.